Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | RAD52 | P43351 | 2/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.43 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | HTR1A | P08908 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3315742 | 0.86 | KDM4E (0.46) | KDM4EALDH1A1SMN1; SMN2MAPTCYP2C9 | |
| SCHEMBL5837430 | 0.85 | KDM4E (0.38) | KDM4EALDH1A1SMN1; SMN2MAPTRAD52 | |
| SCHEMBL6592711 | 0.84 | SMN1; SMN2 (0.50) | KDM4EALDH1A1SMN1; SMN2MAPTCYP2C9 | |
| SCHEMBL11995606 | 0.84 | ALDH1A1 (0.50) | KDM4EALDH1A1SMN1; SMN2MAPTCYP2C9 | |
| SCHEMBL7443823 | 0.83 | SMN1; SMN2 (0.46) | KDM4EALDH1A1SMN1; SMN2MAPTCYP2C9 | |
| SCHEMBL1852173 | 0.79 | SMN1; SMN2 (0.46) | KDM4EALDH1A1SMN1; SMN2MAPTCYP2C9 | |
| SCHEMBL356291 | 0.79 | ALDH1A1 (0.46) | KDM4EALDH1A1SMN1; SMN2CYP2C9CYP1A2 | |
| SCHEMBL6225101 | 0.79 | KDM4E (0.46) | KDM4EALDH1A1SMN1; SMN2CYP2C9CYP1A2 | |
| SCHEMBL12312203 | 0.79 | ALDH1A1 (0.44) | KDM4EALDH1A1SMN1; SMN2CYP2C9CYP1A2 | |
| SCHEMBL11993146 | 0.77 | SMN1; SMN2 (0.44) | KDM4EALDH1A1SMN1; SMN2MAPTCYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8791130-B2 | Aminopyrimidine derivatives as LRRK2 modulators | GENENTECH, INC. (US) | 2014-07-29 | — | — | US | disclosed |
| US-20130158057-A1 | AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS | GENENTECH, INC. (US) | 2013-06-20 | — | — | US | disclosed |
| US-20120122840-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | MYREXIS, INC. (US) | 2012-05-17 | — | — | US | disclosed |
| US-20120122840-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | MYREXIS, INC. (US) | 2012-05-17 | — | — | US | disclosed |
| US-20120122840-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | MYREXIS, INC. (US) | 2012-05-17 | — | — | US | disclosed |
| EP-1981876-B1 | TRIAZOLOANILINOPYRIMIDINE DERIVATIVES FOR USE AS ANTIVIRAL AGENTS | ARROW THERAPEUTICS LTD (GB) | 2011-05-04 | — | — | EP | disclosed |
| WO-2010111406-A2 | COMPOUNDS AND THERAPEUTIC USES THEREOF | MYRIAD PHARMACEUTICALS, INC. (US) | 2010-09-30 | — | — | WO | disclosed |
| US-20100158863-A1 | TRIAZOLOANILINOPYRIMIDINE DERIVATIVES FOR USE AS ANTIVIRAL AGENTS | ARROW THERAPEUTICS LIMITED (GB) | 2010-06-24 | — | — | US | disclosed |
| US-5801170-A | Heterocyclic biphenylylamides useful as 5HT1D antagonists | SMITHKLINE BEECHAM PLC (GB) | 1998-09-01 | — | — | US | disclosed |
| EP-0733048-A1 | HETEROCYCLIC BIPHENYLYLAMIDES USEFUL AS 5HT1D ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1996-09-25 | — | — | EP | disclosed |
| WO-1995015954-A1 | HETEROCYCLIC BIPHENYLYLAMIDES USEFUL AS 5HT1D ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1995-06-15 | — | — | WO | disclosed |
| US-4783467-A | Tetrahydroimidazoquinazolinone inotropic agents | PFIZER INC. (US) | 1988-11-08 | — | — | US | disclosed |
| EP-0205280-A2 | Tetrahydroimidazoquinazolinone cardiac stimulants | Pfizer Limited (GB) | 1986-12-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100158863-A1 | TRIAZOLOANILINOPYRIMIDINE DERIVATIVES FOR USE AS ANTIVIRAL AGENTS | SLC28A1, TPMT, ACE | KDM4E 3988/4885ALDH1A1 443/4885SMN1; SMN2 1198/4885 |
| US-20120122840-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | VHL, TP53, ASAH2 | KDM4E 3146/4885ALDH1A1 238/4885SMN1; SMN2 970/4885 |
| US-20130158057-A1 | AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS | LRRK2, PARK7, P2RX6 | KDM4E 2484/4885ALDH1A1 2148/4885SMN1; SMN2 178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.